Prediction of cognitive response to surgery in elderly patients with primary hyperparathyroidism

A. Koman 1,2,*, R. Bränström 1,2, Y. Pernow 2, R. Bränström 3 and I.-L. Nilsson 1,2

1Department of Endocrine Tumours and Sarcoma, Karolinska University Hospital, Stockholm, Sweden
2Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
3Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

*Correspondence to: Department of Molecular Medicine and Surgery, Karolinska Institutet, SE-171 76 Stockholm, Sweden (e-mail: anna.koman@ki.se)

Abstract

Background: Primary hyperparathyroidism (pHPT) can be associated with potentially reversible cognitive impairment, which is occasionally mistaken for natural ageing and dementia. The aim was to evaluate short-term medical normalization of hypercalcaemia in surgical decision-making for elderly patients with mild cognitive deficiency.

Methods: Patients with pHPT were included in a prospective observational study. A test panel including the Montreal Cognitive Assessment (MoCA) and validated tools for estimation of psychological status (Hospital Anxiety and Depression Scale, HADS), and muscle strength (timed-stands test, TST) was applied at baseline, after 4 weeks of calcimimetic treatment, and after parathyroidectomy. Mild cognitive impairment was defined by a MoCA score below 26. A longitudinal increase in MoCA score of at least 2 points 6 months after surgery was considered clinically meaningful.

Results: Of 110 patients who underwent testing, 35 aged 50 years or more were identified to have mild cognitive dysfunction, including 19 who were aged at least 70 years (median MoCA score 23, i.q.r. 21–24). Calcimimetic treatment resulted in normalization of calcium levels, and improvements in MoCA and HADS scores, and TST time. Normal MoCA scores (at least 26) were reached in 17 patients by 6 months after surgery, of whom 10 were aged 70 years or older. Long-term increase in MoCA score correlated with the decrease in ionized calcium concentration ($r = -0.536$, $P = 0.022$). Baseline calcium concentration and improvement in MoCA with calcimimetic treatment were identified as independent predictors of favourable outcome after parathyroidectomy.

Conclusion: Medical normalization of hypercalcaemia can aid in predicting outcome after parathyroidectomy.

Introduction

Primary hyperparathyroidism (pHPT) is characterized by a relative excess of parathyroid hormone with hypercalcaemia. The cause is most commonly a benign parathyroid adenoma, and the only curative treatment is parathyroidectomy. Conservative treatment can be adopted in asymptomatic disease, or calcimimetic treatment used to reduce symptoms of hypercalcaemia. The incidence of pHPT is largely unknown.

Previous studies have demonstrated that surgical cure rates and clinical outcomes, including morbidity and mortality, are similar in the elderly to those among younger patients. Besides increased fracture-free survival after parathyroidectomy, the majority of elderly patients with pHPT experience general symptoms after parathyroidectomy has been established in both normocalcaemic and hypercalcaemic patients with pHPT, with increasing age, elderly patients are less frequently referred for parathyroidectomy. Predicting the outcome of non-specific symptoms and cognitive performance after parathyroidectomy remains a crucial question.

Short-term medical normalization of hypercalcaemia has been recognized as a feasible diagnostic method that might be
used to predict the overall effects on QoL, cognition, and muscle strength after parathyroidectomy to aid in the decision to offer surgical treatment. A study\(^8\) confirmed that symptom relief achieved by medical normalization of hypercalcaemia correlated well with improvements after surgery. The calcium-lowering effect is almost immediate and reversed rapidly when the drug is discontinued. In a study\(^9\) of 22 patients with pHPT who received 30–50 mg cinacalcet twice daily, normal calcium levels were achieved after only the second dose on day 1, whereas another study\(^10\) with the same agent reported normalization of hypercalcaemia among 14 of 17 patients with intractable pHPT. Although adverse effects were common, a significant improvement in QoL and cognitive functioning was observed\(^10\). There is, however, no convincing evidence for long-term effects of calcimimetic treatment on non-specific symptoms, or its effects on risk reduction for cardiovascular complications or prevention of osteoporosis. Based on its described properties, cinacalcet was considered to be a highly suitable drug for trial purposes to see whether short-term outcomes might predict long-term changes in cognitive function. This study therefore sought to evaluate short-term calcimimetic treatment as a diagnostic tool to predict outcome after parathyroidectomy in elderly patients with pHPT and mild cognitive impairment.

**Methods**

Factors influencing recovery after normalization of hypercalcaemia were analysed in a prospective observational study of patients with pHPT, who were treated with a short-term calcimimetic as a diagnostic tool to predict outcome after parathyroidectomy (ClinicalTrials.gov, NCT00982722). Some of the results have been presented previously, including a detailed description of the study procedure\(^6\). Each patient gave written consent to participate in the study, which was approved by the Swedish Medical Products Agency and the regional ethics committee. This part of the study focused on patients in the cohort aged 50 years or more with mild cognitive impairment as defined below.

Patients received calcimimetic treatment for 4 weeks, followed by parathyroidectomy. Treatment was initiated with 30 mg cinacalcet hydrochloride daily (Mimpara\(^\text{®}\); Amgen, Thousand Oaks, California, USA)\(^11\). If hypercalcaemia persisted after 2 weeks of daily 30 mg cinacalcet, the dose was increased to 60 mg. Calcium levels and side-effects were monitored and recorded weekly during this treatment. BP and levels of ionized calcium were recorded at all other assessments as detailed below.

A panel of validated tests to estimate cognitive function, mental status, and muscle strength was applied four times: at baseline, after 4 weeks of calcimimetic medication, and at 6 weeks and 6 months after parathyroidectomy. Specific length of time was mandated for the interval between cessation of calcimimetic treatment and the date of surgery. Test results were analysed longitudinally in order to compare the effect of normalization of hypercalcaemia with the result after parathyroidectomy. Positive (PPVs) and negative (NPVs) predictive values were calculated for each test.

The Montreal Cognitive Assessment (MoCA)\(^12\)\(^,\)\(^13\), a validated screening instrument for early screening of cognitive impairment, was used. Normative scores for the MoCa, based on a large Swedish population of individuals aged 65–85 years, have been published\(^14\). Visuospatial and abstraction capacity, memory, executive capability, attention, language, and orientation in time and space are evaluated. The maximum score is 30 points. Age and education have an impact on the results. For individuals with 12 years or less of education, 1 point is added to the total score. A score of below 26 points is established as the cut-off value for indicating mild cognitive impairment. Alzheimer’s disease should be considered for a score of less than 22 points.

The Hospital Anxiety and Depression Scale (HADS) questionnaire includes six items for the detection of depression (HADS D) and six for anxiety (HADS A)\(^15\). Each item is scored on a scale of 0–4, lower scores being favourable.

The timed-stands test (TST) is used to estimate proximal muscle strength by measuring the time required to complete 10 full stands from a sitting position as quickly as possible. The time is rounded off to the nearest tenth of a second. A reduction in time

### Table 1 Clinical characteristics

| All ages and MoCA scores | MoCA score < 26, age ≥ 50 years | MoCA score < 26, age ≥ 70 years | Normal reference range |
|--------------------------|---------------------------------|---------------------------------|-----------------------|
| Age (years)\(^1\)         | 62 (53–72)                      | 71 (62–79)                      | 77 (72–82)            |
| Sex ratio (F : M)         | 91 : 19                         | 31 : 4                          | 17 : 2                |
| BMI (kg/m\(^2\))         | 26 (23–29)                      | 27 (23–30)                      | 26 (21–30)            |
| Biochemical measurements  |                                 |                                 |                       |
| Plasma calcium (mmol/l)  | 2.60 (2.51–2.68)                | 2.62 (2.49–2.71)                | 2.67 (2.56–2.73)      |
| Plasma albumin (g/l)     | 38 (36–39)                      | 38 (35–39)                      | 36 (34–39)            |
| Plasma parathyroid hormone (pmol/l) | 10.0 (7.9–13.0) | 11.0 (8.8–14.2) | 11.0 (8.1–14.0) | 1.6–6.0 |
| Plasma phosphate (mmol/l) | 0.86 (0.78–0.95)               | 0.85 (0.78–0.95)               | 0.83 (0.78–0.93)      | 0.8–1.5          |
| Plasma creatinine (μmol/l) | 68 (62–78)                    | 69 (61–81)                      | 69 (60–81)            | < 90 (F)          |
| Serum 25-hydroxy vitamin D (nmol/l) | 66 (52–81)                   | 65 (49–73)                      | 66 (50–76)            | 50–250            |
| Thyroid-stimulating hormone (mE/l) | 1.8 (1.2–2.6)             | 1.8 (1.1–2.6)                   | 1.6 (1.1–2.4)         | 0.3–4.2           |
| Fasting blood glucose (mmol/l) | 5.6 (5.3–5.9)                | 5.6 (5.2–6.1)                   | 5.5 (5.0–6.4)         | 4.0–6.0           |
| Systolic BP (mmHg)\(^1\) | 142 (130–154)                  | 148 (139–175)                   | 151 (134–180)         | 140–155           |
| Diastolic BP (mmHg)      | 88 (82–96)                      | 92 (84–100)                     | 90 (80–100)           | 60–80             |
| Increased dose of calcimimetic | 39                     | 15                               | 9                     |                   |
| Adrenona weight (mg)     | 356 (260–633)                   | 468 (300–1000)                  | 370 (322–925)         |

* Values are median (i.q.r.).  \(^1\) Montreal Cognitive Assessment (MoCA) score 26 (i.q.r. 24–28).
spent performing the test indicates an improvement in proximal muscle strength.\(^{(16)}\)

Blood samples were collected with the patient in a fasting state before each visit. All biochemical analyses were performed using routine methods by the Karolinska University Laboratory in Stockholm. Blood analysed for ionized calcium was delivered within 1 h, and centrifuged within 2 h of collecting the sample.

Glomerular filtration rate was calculated from preoperative baseline blood samples using the Modification of Diet in Renal Disease formula: \(175 \times (\text{serum creatinine/88.4})^{-1.154} \times (\text{age})^{-0.203} \times (0.742 \text{ if female})\).

### Statistical analysis

Based on the distribution, non-parametric methods were used and data presented as median (i.q.r.). All tests were two-tailed, and \(P < 0.050\) was considered statistically significant. Each patient served as their individual control. Wilcoxon signed-rank test was used for intraindividual comparisons. The Spearman rank-order test was used to analyse bivariate correlations. The improvements in each test were transformed into dichotomous variables. For the subgroup with mild cognitive impairment, cross-tabulation was used for calculating specificity, PPV, and NPV for each test. The area under the curve was estimated by receiver operating characteristic (ROC) curve analysis. A binary logistic regression model, including the whole study cohort, was used for analysis of predictors of long-term increase in MoCA score by at least 2 points, as defined by the test developer to be clinically significant.\(^{(17)}\) Statistical analyses were done using SPSS\(^{®}\) version 26 (IBM, Armonk, New York, USA)

### Results

Clinical characteristics of the study cohort and subgroups are shown in Table 1. Of 110 patients enrolled, mild cognitive dysfunction, defined by a MoCA score below 26 (median 23, i.q.r. 21–24), was identified in 35 patients aged 50 years or more (19 patients aged at least 70 years). Overall, 17 of 35 patients (10 aged at least 70 years) had normal MoCA scores of 26 or higher within 6 months after surgery (Fig. 1). A binary logistic regression model identified an increase in MoCA score during calcimimetic treatment and the baseline ionized calcium level, classified into tertiles, as independent predictors of long-term improvement in MoCA score (Table S1).

All but three of the 35 patients with mild cognitive impairment completed the study. Two patients stopped the medication because of gastrointestinal side-effects and one discontinued medication after an upper respiratory tract infection. Parathyroidectomy was performed at a median of 6 (i.q.r. 4–12) weeks after the last dose of study medication.

A total of 15 patients (9 aged at least 70 years) required higher-dose calcimimetic treatment (60 mg/day) to achieve normal calcium levels. No serious adverse event related to the study medication was observed. Calcimimetic treatment resulted in normalization of calcium levels and improvements in MoCA score (change compared with baseline in patients aged 50 years or more: median 2, i.q.r. 0–3; \(P < 0.001\)), HADS score (–2, 0 to –3; \(P = 0.020\)) and TST (–3 (0 to –9) s; \(P = 0.004\) (Table 2). The baseline MoCA score correlated inversely with age \((r = –0.430, P = 0.010)\) but not with the ionized calcium level \((r = 0.079, P = 0.651)\).

The predictive values of tests in the panel are presented in Table 3. HADS had the highest accuracy with PPV and NPV around 90 per cent. MoCA and TST had PPV values around 80 per cent, but an NPV of no more than 33 per cent.

For patients aged at least 70 years, long-term improvement in MoCA score after parathyroidectomy correlated with the decrease in ionized calcium level \((r = –0.526, P = 0.022)\) (Fig. 2).

The decrease in HADS during calcimimetic treatment correlated with an increase in MoCA score 6 months after parathyroidectomy \((r = –0.488, P = 0.047)\) (Fig. 3).

### Discussion

Preservation of cognition, psychological functioning, and muscular strength are important in maintaining QoL and health in the elderly. Exclusion of patients from surgery who exhibit these non-specific manifestations of pHPT is of concern.

It is well recognized that calcimimetic treatment is effective in normalizing calcium levels in pHPT\(^{(18)}\), but adverse effects are frequent and the effect on the calcium concentration lasts only during continuous medication. Short-term normalization of hypercalcaemia has been suggested as a feasible diagnostic tool to predict outcomes after parathyroidectomy. The present study has confirmed that short-term improvements in cognitive function achieved in this way can be maintained for at least 6 months after surgery.

All assessments included in the test panel were performed easily and generated high predictive values regarding long-term benefits of parathyroidectomy. The MoCA screening test, which has been well validated for the detection of cognitive deficiency, and considered appropriate as a repeatable brief measure of longitudinal cognitive change\(^{(13,19)}\), indicated that half of the patients

### Table 2 Test results in patients aged at least 50 years with a Montreal Cognitive Assessment score below 26 at baseline

|                  | Baseline | \(\Delta\)I–II | \(P\) (I versus II)* | \(\Delta\)I–IV | \(P\) (\(\Delta\)I–II versus \(\Delta\)I–IV)* |
|------------------|----------|----------------|---------------------|----------------|----------------------------------|
| **Age ≥ 70 years (n = 19)** |          |                |                     |                |                                  |
| MoCA score       | 22 (20–24) | 1 (0–3)       | 0.004               | 2 (0–4)        | 0.358                            |
| Timed-stands test (s) | 32 (26–45) | –3 (1 to –9)  | 0.061               | –4 (–2 to –15) | 0.006                            |
| HADS anxiety score | 4 (2–10)  | –1 (0 to –3)  | 0.505               | –1 (0 to –3)   | 0.189                            |
| HADS depression score | 4 (1–8)  | –1 (0 to –3)  | 0.053               | –1 (0 to –3)   | 0.189                            |
| HADS total score  | 8 (5–15)  | –2 (0 to –3)  | 0.095               | –3 (0 to –6)   | 0.073                            |
| **Age ≥ 50 years (n = 35)** |          |                |                     |                |                                  |
| MoCA score       | 23 (21–24) | 2 (0–3)       | < 0.001             | 2 (1–4)        | 0.091                            |
| Timed-stands test (s) | 33 (28–40) | –3 (0 to –9)  | 0.004               | –5 (–2 to –10) | 0.033                            |
| HADS anxiety score | 6 (4–10)  | –1 (0 to –2)  | 0.140               | –2 (0 to –3)   | 0.040                            |
| HADS depression score | 4 (1–6)  | –1 (0 to –2)  | 0.019               | –3 (0 to –6)   | 0.040                            |
| HADS total score  | 8 (6–16)  | –2 (0 to –3)  | 0.020               | –3 (0 to –6)   | 0.005                            |

Values are median (i.q.r.). Intraindividual changes are shown \(\Delta\)I–II, change between baseline (measurement I) and after 4 weeks of calcimimetic treatment (measurement II); \(\Delta\)I–IV, change between baseline and 6 months after parathyroidectomy. MoCA, Montreal Cognitive Assessment; HADS, Hospital Anxiety and Depression Scale. * Wilcoxon signed-rank test.
with a baseline score of less than 26 had normal scores 6 months after operation, irrespective of age. These results demonstrate the potential benefit on cognitive function, and underline the importance of establishing a correct indication for parathyroidectomy.

The short-term improvement in depression and anxiety after medical normalization of hypercalcaemia was also found to be associated with long-term effects on cognitive function 6 months after parathyroidectomy. This adds further support for consideration of non-specific symptoms in future guidelines for parathyroid surgery.

Ionized calcium is considered to be the most appropriate measure of hypercalcaemia and was the modality used primarily in the present analysis. The study cohort included patients with pHPT with a range of calcium levels, but the majority had mild hypercalcaemia. Only 3 of 19 patients aged 70 years or more had a calcium level that alone was considered an indication for parathyroidectomy according to the guidelines. The MoCA score at baseline was related to age, but did not correlate with the level of hypercalcaemia. On the other hand, the baseline calcium level was identified as an independent predictor of long-term increase in MoCA score after parathyroidectomy in the whole cohort, as well as in the older age group in whom the long-term increase in MoCA score correlated with the decrease in calcium level.

The study has limitations. The cohort of elderly patients was relatively small. The presence of co-morbidities could have affected the results through changes in other conditions. Before inclusion, all patients had been selected for parathyroidectomy.

### Table 3 Prediction of improvement at follow-up 6 months after parathyroidectomy in patients aged at least 50 years and with a Montreal Cognitive Assessment score below 26 at baseline

|                | PPV (%) | NPV (%) | Sensitivity (%) | Specificity (%) | AUC for ΔI–II |
|----------------|---------|---------|-----------------|-----------------|---------------|
| **Age ≥ 70 years (n = 19)** |         |         |                 |                 |               |
| MoCA score     | 82      | 33      | 69              | 50              | 0.596 (0.263, 0.929) |
| Timed-stands test | 89      | 25      | 73              | 50              | 0.569 (0.209, 0.930) |
| HADS anxiety score | 94      | 56      | 68              | 90              | 0.669 (0.394, 0.945) |
| HADS depression score | 80      | 88      | 89              | 78              | 0.833 (0.629, 1.000) |
| HADS total score | 90      | 100     | 100             | 89              | 0.944 (0.891, 1.000) |
| **Age ≥ 50 years (n = 35)** |         |         |                 |                 |               |
| MoCA score     | 86      | 22      | 72              | 40              | 0.560 (0.273, 0.847) |
| Timed-stands test | 94      | 33      | 74              | 75              | 0.745 (0.474, 1.000) |
| HADS anxiety score | 94      | 56      | 68              | 90              | 0.791 (0.626, 0.956) |
| HADS depression score | 75      | 83      | 88              | 67              | 0.775 (0.603, 0.946) |
| HADS total score | 80      | 92      | 94              | 75              | 0.846 (0.700, 0.991) |

Values in parentheses are 95 per cent confidence intervals. The predictive values of the different components of the test protocol were evaluated dichotomously based on improvement or not. Sensitivity, specificity, and positive (PPV) and (NPV) predictive values were calculated by cross-tabulation. AUC, area under the receiver operating characteristic (ROC) curve; ΔI–II, change between baseline and after 4 weeks of calcimimetic treatment; MoCA, Montreal Cognitive Assessment; HADS, Hospital Anxiety and Depression Scale.
and the outcome could have been affected by patients’ expectations of improvement. The MoCA score also has limitations. Being primarily a screening assessment tool for detecting cognitive deficiencies, the score cannot constitute a basis for detailed neurodegenerative diagnostics. This study model permits limited conclusions about the causality of the cognitive processes related to pHPT.

The results of the present study, however, indicate that there are complex interrelationships between physical, psychological, and cognitive symptoms, and this test panel provides a useful way of predicting outcome after parathyroidectomy. The results emphasize the importance of paying greater attention to a wider assessment of domains that contribute to health-related QoL and the benefits that can be gained after parathyroidectomy, particularly in the elderly. Medical normalization of hypercalcaemia can, regardless of age, help in predicting outcomes after parathyroidectomy and is worthy of wider assessment as an aid to patient selection for surgery.

**Funding**

Novo Nordisk Foundation
Amgen, Solna
Magnus Bergvall Foundation
Fredrik and Ingrid Thuring Foundation
Lisa and Johan Gro¨nberg Foundation

**Acknowledgements**

The research team thank the participating patients for their cooperation, staff at the Department of Endocrine Tumours and Sarcoma, Karolinska University Hospital, for enhancing recruitment of study patients; and R. Hallbeck, research nurse, who assisted in most of the practical testing, and monitored and kept in touch with the study patients throughout the study. This study was funded by Stockholm County Council, Karolinska Institutet, the Novo Nordic Foundation, Amgen, Solna, the Magnus Bergvall Foundation, the Fredrik and Ingrid Thuring Foundation, and the Lisa and Johan Gro¨nberg Foundation.

Disclosure. The authors declare no conflict of interest.

**Supplementary material**

Supplementary material is available at BJS Open online.

**References**

1. Khan AA, Hanley DA, Rizzoli R, Rollerslev J, Young JE, Rejnmark L et al. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management: A Canadian and international consensus. Osteoporos Int 2017;28:1–19

2. Siilin H, Rastad J, Ljunggren O, Lundgren E. Disturbances of calcium homeostasis consistent with mild primary hyperparathyroidism in premenopausal women and associated morbidity. J Clin Endocrinol Metab 2008;93:47–53

3. Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelson R, Marcocci C et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99:3561–3569

4. Yeh MW, Wiseman JE, Ituarte PH, Pasternak JD, Hwang RS, Wu B et al. Surgery for primary hyperparathyroidism: are the consensus guidelines being followed? Ann Surg 2012;255:1179–1183

5. Wu B, Haigh PJ, Hwang R, Ituarte PH, Liu IL, Hahn TJ et al. Underutilization of parathyroidectomy in elderly patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2010;95: 4324–4330

6. Calò PG, Medas F, Loi G, Pisano G, Sorrenti S, Erdas E et al. Parathyroidectomy for primary hyperparathyroidism in the elderly: experience of a single endocrine surgery center. Aging Clin Exp Res 2017;29(Suppl):15–21

7. Bannani S, Christou N, Guerin C, Hamy A, Sebag F, Mathonnet M et al. Effect of parathyroidectomy on quality of life and non-specific symptoms in normocalcaemic primary hyperparathyroidism. Br J Surg 2018;105:223–229

8. Koman A, Ohlsson S, Branstrom R, Pernow Y, Branstrom R, Nilsson IL. Short-term medical treatment of hypercalcaemia in primary hyperparathyroidism predicts symptomatic response after parathyroidectomy. Br J Surg 2019;106:1810–1818

9. Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003;88:5644–5649

10. Marcocci C, Chanson P, Shoback D, Bilezikian J, Fernandez-Cruz L, Orgiazzi J et al. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab 2009;94:2766–2772

11. Amgen. Highlights of Prescribing Information. 2004, https://www.pi.amgen.com/~/media/amgen/repository/sites/pi-amgen-com/sensipar/sensipa

12. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695–699

13. Dalrymple-Alford JC, MacAskill MR, Nakas CT, Livingston L, Graham C, Crucian GP et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 2010;75:1717–1725

14. Borland E, Nagga K, Nilsson PM, Minthon L, Nilsson ED, Palmqvist S. The Montreal cognitive assessment: normative data from a large Swedish population-based cohort. J Alzheimers Dis 2017;59:893–901

15. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361–370

16. Tsui M, Biesada C, Shiel JW, Grima D, O’Driscoll T et al. Simultaneous presentation of MoCA and HADS-A in clinicopathological conditions of cognitive impairment. Acta Psychiatrica Scand 2011;124:48–53

17. Nasreddine ZS, Patel BB. Validation of Montreal Cognitive Assessment, MoCA, Alternate French Versions. J Neurosurg 2018;188:665–671

18. Brown EM. Clinical utility of calcimimetics targeting the extracellular calcium-sensing receptor (CaSR). Biochem Pharmacol 2010;80:297–307

19. Krishnan K, Rossetti H, Hynan LS, Carter K, Falkowski J, Lacritz L et al. Changes in Montreal Cognitive Assessment scores over time. Assessment 2017;24:772–777

20. Wilhelm SM, Wang TS, Ruan DT, Lee JA, Asa SL, Duh QY et al. The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism. JAMA Surg 2016;151:959–968